Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is ...

WASHINGTON, Sept 10 (Reuters) - A federal advisory panel recommended approval of GlaxoSmithKline Plc's new drug to treat chronic obstructive pulmonary disease(COPD ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...

Carl Battle has a big job on his hands managing pharmaceutical giant GlaxoSmithKline’s patent team. Michael Loney talks to him and some of his staff about bringing Anoro Ellipta to market, the dreaded ...

Anoro Ellipta generic Anoro Ellipta is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active ingredient in a brand-name ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...